Ipsen Shares Break Through Their €159.40 Resistance and Target €172.90
The Paris-based laboratory extends its recovery in a rising Parisian market. The stock is approaching a ceiling tested for several weeks, following a quarterly release that had raised the group's targets.
A Breakout That Consolidates the Stock's Upward Trend
Ipsen gains 2.14% to €162.10 intraday, while the CAC 40 rises 0.35% and the SBF 120 advances 0.37%. The stock has broken above its highest level of the past thirty sessions, at €159.40, a level that now serves as support.
The momentum is clear: the stock is 6.5% above its 50-day moving average (€152.27) and has gained 14.6% over one month. The next benchmark is resistance at €172.90. The move follows sales up 24.6% over nine months, published on October 22 with a further upward revision of annual targets.
Risks Cited by Ipsen: a Somatuline Generic and Arbitration Proceedings
When publishing its results for the first nine months of 2026 on October 22, the group highlighted several risks. Among them is the early entry of a generic lanreotide in the fourth quarter, which would weigh on Somatuline sales. The group also cited arbitration proceedings initiated by Galderma concerning corabotase, the financial impact of which cannot reasonably be predicted.
On the outlook side, the company highlighted ongoing regulatory submissions for Dysport in migraine and for Iqirvo in primary biliary cholangitis.
For the latter product, the Phase III ELSPIRE study, unveiled on November 5, showed normalization of ALP in 85.3% of patients, compared with 23.3% under placebo. According to the consensus of the analysts surveyed, the stock trades at about 10 times expected earnings for the current fiscal year.
